Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.
about
Hepatitis B: the virus and diseasePseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cellsReview of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyChange of strategies and future perspectives against hepatitis B virus recurrence after liver transplantationNew virologic tools for management of chronic hepatitis B and CRecent advances in understanding and diagnosing hepatitis B virus infectionAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Recent advances in micro/nanotechnologies for global control of hepatitis B infectionLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.A cutting-edge view on the current state of antiviral drug development.Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantificationComplex dynamics of hepatitis B virus resistance to adefovir.Antiviral treatment of chronic hepatitis B virus (HBV) infectionsVirologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy.Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Current status of antiviral therapy for hepatitis BTherapeutic implications of hepatitis C virus resistance to antiviral drugs.An overview of treatment response rates to various anti-viral drugs in Pakistani hepatitis B virus infected patientsAdding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR.Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).Tenofovir rescue therapy in pregnant females with chronic hepatitis BGenotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy.Performance characteristics and comparison of Abbott and artus real-time systems for hepatitis B virus DNA quantificationDisease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy.A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.Antiviral therapies: focus on hepatitis B reverse transcriptaseBaseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced CirrhosisComparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysisAustralian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis BEfficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.Differences in metabolites of different tongue coatings in patients with chronic hepatitis B.Monitoring during and after antiviral therapy for hepatitis B.Antiviral resistance and hepatitis B therapy.Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial.Resistance issues in treating chronic hepatitis B.
P2860
Q24642704-A74F1F05-3706-404A-8EA6-0991F6F12FBBQ24648726-7C02E3F4-652F-4AFB-844F-BA5A046FDF7DQ26740161-F888E41D-E4D5-4A98-8058-B2B072157E0BQ26784241-CFCD9D14-C4FA-4A3A-BB39-4D0834EB1199Q27026914-72AA7540-ADCC-41E9-B6FC-2543AE982007Q28067419-F81B684B-D516-46A9-86E4-9247404575A0Q28535003-4A79CBEB-282E-4696-A5E1-7FFD925795ECQ30391932-FCD1E292-BB54-45B0-9F2A-26C7C93549B8Q30394611-48481A24-B37A-4E45-A201-D14906E6FC93Q33417353-DA9BA505-08FD-46A6-B2F7-888F978D0C96Q33848190-6AEC111B-3437-4991-9BF9-094D31BB8B7AQ33985364-E68D59D4-C8D8-4290-AA82-ACC6036B88BFQ34036018-338157B4-08FC-4E46-9BE5-3A359CB9B770Q34190314-DC3025A9-BA4A-47C3-B610-70ECD6A7AB56Q34208672-155520BC-CA13-4917-9D30-D5EB011E0771Q34223779-0619BF72-F29B-44FF-BED0-65CE5A128387Q34303163-9CC740E3-CF9E-4F03-9215-4DB26D3F38D2Q34339608-C10E5EE5-8B1D-46A9-8DDD-ACDCEF0AA5AAQ34408879-85F29DCC-AB9F-4DDA-9355-FE9704683A60Q34409020-1F473928-F735-427C-927D-2D1885C72391Q34522022-29A1BC65-8C47-44AD-A6CC-327F92E3B18AQ34538293-1F213257-FC82-41C9-B689-30040760A799Q34685945-97958AAA-A683-4424-B1D5-C594BA4B0A87Q34693445-B5B5F1D6-17A7-4E02-A669-C4F205DD9ECBQ35128259-9B1AB961-BB8B-48AE-8570-CFBA029CA463Q35186029-E87921DD-3190-4EE9-9C90-E20E035B1913Q35192257-133CF5D7-A6B5-4E16-91C5-089C1976E1D5Q35551316-5B1C144B-E55B-4913-8706-37BEE9CD0827Q35778059-FDD1A7E7-F6E9-4FED-9F24-82B024DCC4E3Q36467514-7E05F23D-87AF-4E9E-8F4A-61F5A526BD03Q36477102-568CF076-0C2B-42B2-8F9A-C843747F2A9FQ36492635-60197FFA-E2E6-4D15-8377-A499ED4108DBQ36615961-7198FD76-11E1-4086-990F-39795DBD7CA5Q36745002-2ED61EBD-5769-4778-A2C5-D954137BF9A7Q36838273-6B4D426A-3053-40A8-8811-712AA9BB1723Q37186162-68EAC618-8EBB-42C0-A5CD-74B70752E84EQ37255008-48EE4FA0-084A-4EA8-A0CE-3296D8C94C87Q37272140-BA4D31BA-E95A-465A-803F-2EFC2F2B2CDEQ37274078-3FCC2C41-A8DC-409A-9A24-8AF24471F852Q37277073-87117DFE-7592-41FD-8587-303B5A50D6D4
P2860
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Virologic monitoring of hepati ...... s for a standardized approach.
@en
Virologic monitoring of hepati ...... s for a standardized approach.
@nl
type
label
Virologic monitoring of hepati ...... s for a standardized approach.
@en
Virologic monitoring of hepati ...... s for a standardized approach.
@nl
prefLabel
Virologic monitoring of hepati ...... s for a standardized approach.
@en
Virologic monitoring of hepati ...... s for a standardized approach.
@nl
P2093
P2860
P1433
P1476
Virologic monitoring of hepati ...... s for a standardized approach.
@en
P2093
Angelos Hatzakis
Douglas D Richman
Fabien Zoulim
Geoffrey Dusheiko
George Lau
Jean-Michel Pawlotsky
Paul Martin
Stephen Locarnini
T Jake Liang
P2860
P304
P356
10.1053/J.GASTRO.2007.11.036
P407
P577
2007-11-28T00:00:00Z